Share-based Compensation (Tables)

12 Months Ended

Jun. 30, 2016

Share-based Compensation

Schedule of weighted average assumptions used to estimate fair values of the stock options granted and the estimated annual forfeiture rates used to recognize the associated compensation expense and the weighted average fair value of the options granted

	June 30, 2016			June 30, 2015			June 30, 2014
Risk-free interest rate	1.7		%	1.7		%	2.1		%
Expected volatility	48.3		%	52.1		%	62.8		%
Expected dividend yield	0.0		%	0.0		%	0.0		%
Forfeiture rate	6.5		%	6.5		%	7.5		%
Expected term	5.2 years			5.5 years			5.9 years
Weighted average fair value	$	26.24		$	17.73		$	8.55

Summary of stock option award activity

							Weighted
			Weighted-				Average
			Average		Aggregate		Remaining
			Exercise		Intrinsic		Contractual
(In thousands, except for weighted average price and life data)	Awards		Price		Value		Life (yrs.)
Outstanding at June 30, 2013	2,319		5.71
Granted	780		13.90
Exercised	(783	)	6.41		$	24,375
Forfeited, expired or repurchased	(111	)	6.49
Outstanding at June 30, 2014	2,205		7.84
Granted	513		36.71
Exercised	(665	)	6.47		$	33,201
Forfeited, expired or repurchased	(78	)	18.33
Outstanding at June 30, 2015	1,975		$	15.39	$	86,983	7.2
Granted	58		59.20
Exercised	(254	)	12.62		$	6,168
Forfeited, expired or repurchased	(49	)	32.66
Outstanding at June 30, 2016	1,730		$	16.77	$	19,524	6.3
Vested and expected to vest at June 30, 2016	1,714		$	16.61	$	19,495	6.2
Exercisable at June 30, 2016	1,238		$	12.31	$	17,462	5.6

Summary of nonvested restricted stock awards

(In thousands)	Awards		Weighted Average Grant - date Fair Value		Aggregate Intrinsic Value
Non-vested at June 30, 2013	—		—
Granted	269		24.07
Vested	(252	)	23.45		$	10,440
Forfeited	(1	)	24.48
Non-vested at June 30, 2014	16		34.01
Granted	103		37.97
Vested	(14	)	36.06		$	664
Forfeited	(7	)	36.59
Non-vested at June 30, 2015	98		$	37.83
Granted	147		54.64
Vested	(66	)	47.11		$	3,511
Forfeited	(12	)	47.67
Non-vested at June 30, 2016	167		$	48.22

Schedule of allocation of share-based compensation costs recognized in the Consolidated Statements of Operations by financial statement line item

	For Fiscal Year Ended June 30,
(In thousands)	2016		2015		2014
Selling, general and administrative expenses	$	9,529	$	5,145	$	7,388
Research and development expenses	760		523		675
Cost of sales	1,273		729		963
Total	$	11,562	$	6,397	$	9,026
Tax benefit at statutory rate	$	4,220	$	2,159	$	3,375